宝泰PM免疫调节剂治疗常年性变应性鼻炎临床疗效观察及免疫机理探讨

Clinical Observation of Perenernial Allergic Rhinitis Patients Treated With B.T PA-MSHA Immunor Regulater

应用宝泰PM免疫调节剂治疗60例常年性变应性鼻炎，根据治疗前后病情分级的改善和变应原鼻粘膜激发试验评定，有效率分别为90％和86．7％。治疗前后血清及鼻分泌物中广谱凝集抗体效价、特异性IgG和SIgA抗体阳性检出率及抗体满度均有不同程度改变，其中血清绿脓杯自MSHA菌毛株凝集抗体液度比治疗前增加4～64倍，鼻分泌物中治疗前后绿脓杆菌菌毛株凝集抗体阳性人数检出率有非常显著性差异（P＜0．005）；治疗后血清中变形杆菌、大肠杆菌、绿脓杆菌菌毛株特异性IgG荧光抗体滴度有一定程度增加，鼻分泌物中绿脓杆菌菌毛株特异性SIgA荧光抗体治疗前后阳性人数检出卓有高度显著性差异（P＜0．005）。本治疗机理是采用低毒、广谱、较强免疫原性的绿脓杆菌MSHA菌毛株菌苗，进行全身免疫治疗，刺激机体产生高效价、跨菌属抗体，并结合其他免疫调节作用达到治疗目的。

Sixty cases of patients with perennial allergic rhinitis were treated with B. T PA - MSHAImmunoregulater. The total effetive rate was about 86. 7 percent accoiding to the clinical conditionimprovements and the allergen intranasal provocation test after two months of therapy. It was found that thetiter of PA-MSHA specific agglutilation antibodies increased 4to 64 times in the sera and its positive rate inthe nasal secretions increased significantly(P<0. 005) ithe PA-MSHA specific SIgA in nasal secretions anda broad cross - reactive agglutilation antibodies also increased in various extent after the therapy. Thetherapeutic machenisms of the B. T PA-MSHA were discussed and it is possible a regulation of non-specificimmunity.